Fosamax (alendronate sodium)Tablets Company: Merck Research Laboratories Application No.: , S Approval Date: 11/24/ Fosamax(Alendronate Sodium) Tablets Company: Merck Research Laboratories Application No.: /S Approval Date: 6/8/ Fosamax Plus D (Alendronate Sodium) Tablets Company: Merck & Co., Inc. Application No.: Approval Date: 04/07/ Approval Letter(s) (PDF).
Fosamax (alendronate sodium): Treatment for osteoporosis in women after menopause and Paget's Disease of Bone. New approved drug details including side. Alendronate Sodium drug usage statistics for the United States ( - ). Statistics include drug synonyms and Initial FDA approval date: 9/29/ FDA approval history for Binosto (alendronate) used to treat Osteoporosis. Supplied Development History and FDA Approval Process for Binosto. Date, Article.
FDA approval history for Fosamax Plus D (alendronate and cholecalciferol) used Fosamax Plus D is a single once-weekly tablet containing the Date, Article. In , the FDA approved alendronate (Fosamax) for the treatment of postmenopausal osteoporosis, a bone-weakening condition that affects. The FDA has approved a generic version of the osteoporosis drug Fosamax ( alendronate). Alendronic acid (INN) or alendronate sodium, sold under the trade name Fosamax among . "New drugs--reports of new drugs recently approved by the FDA.